US $ 24 billion and $ 800 million revenue from Corona vaccine

According to IRNA from CNBC, Johnson & Johnson Company in the report of the fourth quarter of 2021 announced that the net income of the company from the sale of this vaccine has reached 24 billion and 800 million dollars, which compared to the revenue of 22.48 billion dollars. The same quarter in 2020 increased by 10.4%. The increase was mainly due to international sales of the $ 1.82 billion corona vaccine.

Johnson & Johnson also predicted that the company could increase its revenue to $ 3 billion to $ 3.5 billion by 2022 by continuing to sell the Corona vaccine.

Johnson & Johnson’s high revenue in 2021, while in the final month of this year, the US Centers for Disease Control and Prevention recommended that citizens use Pfizer and Maderna vaccines instead of Johnson’s single-dose vaccine.

The US Centers for Disease Control and Prevention also found that dozens of mostly young women developed rare blood clots after receiving the Johnson vaccine.

The Covid-19 Johnson & Johnson vaccine is one of three vaccines approved for use in the United States. This coronavirus, unlike the other two Pfizer and Moderna vaccines, provides complete protection against the coronavirus just by injecting a single dose.

However, this single-dose vaccine appears to be less effective in preventing coronavirus infection than the other two vaccines, as initial clinical trials have shown that the vaccine is effective in preventing Severe coronary heart disease is 85% effective. According to the US Centers for Disease Control and Prevention, vaccines with two doses of modernization and Pfizer are about 90% effective in preventing severe coronary heart disease.